Device and Method for Treating Weight Disorders

• US 20070265598A1
• Filed: 09/29/2005
• Published: 11/15/2007
• Est. Priority Date: 09/30/2004
• Status: Abandoned Application

• Current Assignee: Duocure, Inc.
• Original Assignee: Duocure, Inc.
• Inventors: Karasik, Yael
• Application Number:
  US11/663,222
• Publication Number:
  US 20070265598A1
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/392 Detecting gastrointestinal contractions
• CPC Class Codes: A61B 5/42 Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems A61B1/00, A61B5/4857, A61B5/486, A61B5/4866, A61B5/4869 take precedence
• CPC Class Codes: A61B 5/4238 stomach
• CPC Class Codes: A61F 5/0026 Anti-eating devices using electrical stimulation
• CPC Class Codes: A61F 5/003 inflatable
• CPC Class Codes: A61F 5/004 remotely adjustable
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/2207 Gastrins; Cholecystokinins [CCK]
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2210/1053 Stomach
• CPC Class Codes: A61M 2210/1057 Duodenum
• CPC Class Codes: A61M 2230/63 Motion, e.g. physical activity
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control

Abstract

An apparatus and a method for treating a weight disorder in a subject are provided. The apparatus comprising an implantable device such as an inflatable balloon and electrodes capable of sensing a physiological change associated with food ingestion or hunger and a mechanism adapted for directly stimulating a region such as the duodenum which is responsive to a gastrointestinal satiety agent, such a mechanism can be a drug reservoir containing a drug such as CCK or analogs thereof which is contained within an inflatable balloon being implantable in a stomach of the subject. The apparatus and method provided here combine synergistic approaches to limiting meal size, i.e., chemo and mechano receptor activation of vagal satiety stimuli, electric stimulation of specific vagal pathways and limitations of gastric space.

Claims

1-54. -54. (canceled)

55. An apparatus for treating a weight disorder in a subject comprising an implantable device capable of sensing a physiological change associated with food ingestion or hunger and a mechanism adapted for directly stimulating a region responsive to a gastrointestinal satiety agent.

56. The apparatus of claim 55, wherein said device capable of sensing a physiological change associated with food ingestion or hunger comprises an inflatable balloon.

57. The apparatus of claim 55, wherein said device capable of sensing a physiological change associated with food ingestion or hunger comprises at least one electrode.

58. The apparatus of claim 55, wherein said implantable device capable of sensing said physiological change associated with food ingestion or hunger comprises a muscle activity sensor.

59. The apparatus of claim 55, wherein said mechanism comprises a drug reservoir being capable of containing and releasing a drug in response to said physiological change associated with food ingestion or hunger sensed by said implantable device.

60. The apparatus of claim 59, said mechanism configured to release said drug to a duodenum wall, to an antral sphincter and/or to a gastrointestinal wall.

61. The apparatus of claim 59, said drug reservoir positioned inside an inflatable balloon.

62. The apparatus of claim 59, further comprising an inflatable balloon implantable within a stomach of the subject, said inflatable balloon capable of activating vagal mechanoreceptors and/or space-filling.

63. The apparatus of claim 59, said mechanism further comprising at least one electrode capable of vagal innervation.

64. The apparatus of claim 63, wherein said at least one electrode capable of vagal innervation is disposed on a balloon implantable within a stomach.

65. The apparatus of claim 63, said mechanism configured to effect said vagal innervation 1-5 minutes following said sensing by said device capable of sensing a physiological change associated with food ingestion or hunger.

66. The apparatus of claim 55, configured for implantation in a stomach.

67. The apparatus of claim 55, said mechanism comprising an injectable device capable of injecting a drug.

68. A method of treating a weight disorder comprising:

a) implanting in a subject in need thereof a device capable of sensing a physiological change associated with food ingestion or hunger;

b) functionally associating with said device, a mechanism adapted for directly stimulating a region responsive to a gastrointestinal satiety agent; and

c) subsequent to sensing a physiological change associated with food ingestion or hunger by said device, activating said mechanism so as to directly stimulate said region.

69. The method of claim 68, wherein said stimulation of said region is effected using a drug.

70. The method of claim 69, wherein said drug is released to a duodenum wall, to an antral sphincter and/or to a gastrointestinal wall.

71. The method of claim 69, wherein said drug is a satiety drug and/or an anti food absorption drug.

72. The method of claim 68, wherein said mechanism comprises a drug reservoir containing a drug;

and further comprising;

releasing said drug from said drug reservoir as said direct stimulation in response to said sensing by said device of said physiological change associated with food ingestion or hunger.

73. The method of claim 68, further comprising implanting in said subject an inflatable balloon capable of activating vagal mechanoreceptors and/or space-filling.

74. The method of claim 73, further comprising:

subsequent to sensing a physiological change associated with food ingestion or hunger by said device, activating vagal mechanoreceptors with said inflatable balloon.

75. The method of claim 68, wherein said mechanism comprises at least one electrode capable of vagal innervation;

and further comprising;

performing vagal innervation with the help of said electrode.

76. The method of claim 68, wherein said device capable of sensing a physiological change associated with food ingestion or hunger comprises at least one electrode.

77. The method of claim 76, wherein said physiological change sensed comprises an electrical activity of a muscle.

78. The method of claim 68, wherein said implantable device capable of sensing said physiological change associated with food ingestion or hunger comprises a muscle activity sensor.

79. The method of claim 68, wherein said device capable of sensing a physiological change associated with food ingestion or hunger is implanted in a stomach of said subject.

80. The method of claim 68, wherein said need of said subject is related to a weight disorder selected from the group consisting of obesity, bulimia, diabetes-related obesity and a metabolic syndrome.

81. An apparatus for treating a weight disorder in a subject comprising an implantable device capable of sensing a physiological change associated with food ingestion or hunger and a mechanism adapted for directly stimulating a region responsive to a gastrointestinal satiety agent, said mechanism comprising an inflatable balloon implantable in a stomach of a subject and a drug reservoir containing a drug capable of stimulating said region, said drug selected from the group consisting of CCK, a CCK analog, a CCK receptor agonist, a PYY, a PYY analog, GLP-1, a GLP-1 analog and oxyntomudulin.

82. The apparatus of claim 81, said drug reservoir being capable of containing and releasing said drug in response to said physiological change associated with food ingestion or hunger.

83. The apparatus of claim 82, said mechanism configured to release said drug from said drug reservoir to a duodenum, to an antral sphincter and/or to an intestine.

84. The apparatus of claim 81, said device capable of sensing a physiological change associated with food ingestion or hunger comprises at least one electrode capable of sensing an electrical activity of a muscle.

85. The apparatus of claim 81, wherein said device capable of sensing a physiological change associated with food ingestion or hunger comprises a pressure sensor.

86. A method of treating a weight disorder comprising:

a) implanting in a subject in need thereof a device capable of sensing a physiological change associated with food ingestion or hunger;

b) functionally associating with said device a mechanism adapted for directly stimulating a region responsive to a gastrointestinal satiety agent, said mechanism comprises an inflatable balloon being implantable in a stomach of the subject and a drug reservoir containing a drug capable of stimulation of said region, said drug is selected from the group consisting of CCK, a CCK analog, a CCK receptor agonist, a PYY, a PYY analog, GLP-1 and GLP-1 analog; and

c) subsequent to sensing a physiological change associated with food ingestion or hunger by said device, releasing said drug from said reservoir.

87. The method of claim 86, wherein said physiological change associated with food ingestion or hunger comprises an electrical activity of a muscle.

88. The method of claim 86, wherein said physiological change associated with food ingestion or hunger comprises a change in pressure in a stomach of said subject.

89. The method of claim 86, wherein said drug is released to a duodenum, to an antral sphincter and/or to an intestine.

90. An apparatus for treating a weight disorder in a subject comprising a distending object being implantable in a stomach of the subject and a drug reservoir containing a drug capable of stimulation a region responsive to a gastrointestinal satiety agent.

91. A method of treatment, comprising:

a) providing a pharmaceutical composition which comprises a peptide drug;

b) releasing said drug to an antral sphincter and/or a gastrointestinal wall so that said drug activates chemoreceptors on said antral sphincter and/or a gastrointestinal wall

thereby causing a beneficial effect.

92. The method of claim 91, wherein said gastrointestinal wall is a duodenum wall.

93. The method of claim 91, wherein said releasing of said drug follows the sensing of food ingestion or hunger.

94. An apparatus for administering a drug to a luminal wall of a portion of the gastrointestinal tract, comprising:

a) a drug dispersing tube and configured to release a drug to an antral sphincter and/or a gastrointestinal wall;

b) a drug releasing mechanism functionally associated with a drug reservoir and with said drug dispering tube, configured to release a dose of drug held in said drug reservoir out through said dispersing tube; and

c) a pharmaceutical composition including a peptide drug held in said drug reservoir.

95. The apparatus of claim 94, said drug is configured to activate chemoreceptors on an antral sphincter and/or a gastrointestinal wall.

96. The apparatus of claim 94, wherein said drug is a synthetic or naturally occurring hormone, peptide, neurotransmitter or mimetic thereof.

97. A method of administering a drug, comprising:

a) deploying a drug dispersing tube of an apparatus of claim 94 in a location of a gastrointestinal tract of a subject suffering from a condition;

b) providing a pharmaceutical composition comprising a peptide drug, said drug effective in treating said condition; and

c) releasing said drug following sensing a physiological change through said dispenser so that said drug directly activates chemoreceptors on an antral sphincter and/or gastrointestinal wall

thereby administering said drug so as to treat said condition.

98. The method of claim 97, wherein said gastrointestinal wall is a duodenum wall.

99. The method of claim 97, wherein said drug is a synthetic or naturally occurring hormone, peptide, neurotransmitter or mimetic thereof.

100. The method of claim 97, wherein said drug is a satiety drug and/or an anti food absorption drug.